Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Denniston

Physician Assistant, Medical Frankfort, KY Physician Assistant

NPI 1124395843 CMS profile 10441177

1001 Leawood Dr Ste C, Frankfort, KY 40601

Open in the dashboard

General payments

$4,652

264 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Denniston of Frankfort, KY is reported in the CMS Open Payments database as having received $4,652 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $785 41
2024 General $1,767 91
2023 General $782 47
2022 General $459 26
2021 General $859 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Denniston
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brittany Denniston were reported at $785. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brittany Denniston Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $859 $156 $41–$563 $132
2022 $459 $185 $55–$649 $149
2023 $782 $199 $58–$717 $160
2024 $1,767 $206 $62–$740 $164
2025 $785 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $810 46 payments
  2. AbbVie, Inc. $722 41 payments
  3. GlaxoSmithKline, LLC. $470 32 payments
  4. Lilly USA, LLC $459 26 payments
  5. Amgen Inc. $371 14 payments
  6. AstraZeneca Pharmaceuticals LP $303 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $280 19 payments
  8. Pfizer Inc. $179 11 payments
  9. Astellas Pharma US Inc $155 9 payments
  10. Novartis Pharmaceuticals Corporation $130 8 payments
  11. Other $773 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,622 263 payments
  2. Education $30 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $705 39 payments
  2. Ozempic $618 32 payments
  3. TRELEGY ELLIPTA $427 29 payments
  4. MOUNJARO $353 19 payments
  5. Repatha $339 12 payments
  6. VRAYLAR $336 13 payments
  7. QULIPTA $316 23 payments
  8. UBRELVY $316 23 payments
  9. JARDIANCE $157 11 payments
  10. AIRSUPRA $156 7 payments
  11. Other $2,512 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

3,126

Median for Physician Assistant: 241

Drug cost

$268,152

Median for Physician Assistant: $4,110

Branded share of claims

20.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 74 $72,796
Ozempic Semaglutide Brand 58 $57,053
Eliquis Apixaban Brand 22 $21,165
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $17,009
Vraylar Cariprazine Hcl Brand 11 $15,629
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 25 $15,308
Januvia Sitagliptin Phosphate Brand 17 $12,303
Mounjaro Tirzepatide Brand 11 $12,097
Farxiga Dapagliflozin Propanediol Brand 11 $10,700
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 11 $3,070

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$26,025

Of which drugs: $5,505

Medicare patients

132

Average age 73

Services billed

579

82 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 23%
Diabetes 21%
Chronic kidney disease 20%
Depression 19%
Atrial fibrillation 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,381
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,054

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $292
$292 11 —
MOUNJARO
  • Lilly USA, LLC $200
$200 11 —
Repatha
  • Amgen Inc. $134
$134 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $115
$115 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $114
$114 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record